Dechra Pharmaceuticals acquires animal medical supplier CaledonianStaff Writer | October 8, 2018
The Board of Dechra announces the acquisition of the trade and assets of Caledonian Holdings Ltd. (Caledonian) for a cash consideration of NZD 8.7 million (£4.4m). Revenue in the year to 30 June 2017 was NZD 3.6 million (£1.8m).
Acquisition Caledonian was established in 2010
Caledonian's range of proprietary equine drugs will enhance our existing portfolio, which includes Osphos®, and will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand. The acquisition will also enable Dechra to grow its market penetration of equine products in the Asian market.
Ian Page, Dechra's chief executive officer commented, "We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand (ANZ) businesses. This will enable Dechra to leverage its position in the ANZ equine market."
Dechra will issue an Annual General Meeting trading update on 19 October 2018. ■